🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Toleranzia AB : Interim report second quarter 2024 storage.mfn.se/c05d731a-da88-…

Toleranzia AB har erhållit teckningsförbindelser avseende nyttjande av teckningsoptioner av serie TO4 motsvarande cirka 71,14 procent storage.mfn.se/5ad25ef1-b066-…

Toleranzia AB has received subscription commitments regarding the exercise of warrants of series TO4 corresponding to approximately 71.14 percent storage.mfn.se/ec20b90e-ea2b-…

BioStock artikel: Fullt fokus på kliniska studier för Toleranzia AB biostock.se/2024/08/fullt-…

Toleranzia AB submits a clinical trial application (CTA) for the drug candidate #TOL2 for the treatment of #myastheniagravis storage.mfn.se/9c36022c-7e43-…

Toleranzia AB ansöker om klinisk prövning av läkemedelskandidaten #TOL2 för behandling av #myastheniagravis storage.mfn.se/b0a4d0f7-299e-…

The exercise period for Toleranzia AB's warrants of series TO4 begins today storage.mfn.se/9b3387c2-8288-…

Nyttjandeperioden för Toleranzia AB s teckningsoptioner av serie TO4 inleds idag storage.mfn.se/2b73aa0c-08f0-…

BioStock artikel: "Höga förväntningar på #TOL2 som nytt säkert och effektivt läkemedel". biostock.se/2024/10/hoga-f…

BioStock artikel: "Världsledande forskare leder Toleranzia AB s kliniska studie" biostock.se/2024/10/varlds…

Hör Toleranzia AB s vd Charlotte Fribert i intervju från Biostock Studio biostock.se/2024/10/tolera…

James Howard, Professor of Neurology, University of North Carolina, and coordinating investigator of Toleranzia AB 's clinical study, gives his view on the lack of adequate treatments for #myastheniagravis linkedin.com/feed/update/ur…

Our CEO, Charlotte Fribert, will present at the 8th Antigen-Specific Immune Tolerance Drug Development Summit in Boston, on February 26th, 2025 at 11:00 She'll talk about proteins as tolerogens to induce antigen-specific immune tolerance Let’s connect! #ASIT2025 #Toleranzia #TOL2

Today, 28 February, is the rarest day of the year for the rarest among us. Toleranzia is pioneering a new era in developing disease-specific and safe therapies for the autoimmune rare diseases #MyastheniaGravis & #ANCAVasculitis #TOL2 #RareDiseaseDay #RareButNotAlone

Happy #InternationalWomensDay 🌍 At Toleranzia, we are proud to uphold a 50-50 gender balance. Scientific breakthroughs know no gender—only passion, knowledge, and the drive to make a difference. Let’s #AccelerateAction for an inclusive future. 💪 #IWD2025 #WomenInSTEM

"This approach allows us to attract specialist investors who typically do not invest in the public market, while current shareholders in Toleranzia retain a liquid share in Flerie," says Ted Fjallman CEO of #Flerie Toleranzia AB nordiclifescience.org/flerie-and-tol…

See you there... Let's connect! #Toleranzia #TOL2 #myastheniagravis #Conference

This MG Awareness Month, join thousands of others in raising awareness about #myastheniagravis – what it’s like to live with this disease, how it impacts your life, and how the MG Community is fighting for “a world without MG.” Take action for MG awareness!

June is Myasthenia Gravis Awareness Month. At Toleranzia, we’re committed to developing #TOL2, a disease-specific tolerogen for MG, designed to re-establish immune tolerance by addressing the root cause of the disease. #MGStrong #MGAwarenessMonth #MyastheniaGravisAwarenessMonth

Symptoms of myasthenia gravis can vary in intensity over the course of a day, and may fluctuate from month to month or year to year. #MGStrong #MGAwarenessMonth #MyastheniaGravisAwarenessMonth